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A B S T R A C T
Objective: Eating disorder symptoms change in a predictable pattern over the menstrual cycle such that changes
in symptoms are triggered by changes in the ovarian hormones estradiol (E2) and progesterone (P4). To date,
work in this area has focused exclusively on young adult women. The objective of this pilot study was to examine
the effect of E2 and P4 on eating disorder symptom change in midlife women during early perimenopause.
Method: Participants included women aged 42–52 in early perimenopause (n = 8). In-home self-assessments
were completed for one menstrual cycle or 40-days, whichever occurred first. In-home self-assessments included
collecting saliva samples each morning for E2 and P4 assays and completing online study questionnaires at the
end of each day. Multilevel regression models examined the associations of E2 and P4 with daily symptoms of
binge eating and body dissatisfaction.
Results: E2 was positively associated with binge eating when P4 was high, but not when P4 was low. E2 was
inversely associated with body dissatisfaction when P4 was low, but positively associated with body dis-
satisfaction when P4 was high. However, the simple slopes for the effect of E2 at both high and low P4 were not
significant for body dissatisfaction.
Conclusions: Despite the pilot nature of this study, results are broadly consistent with the young adult literature
indicating that P4 levels shape the impact of E2 on eating disorder symptoms. Larger studies with the inclusion
of key moderators to account for individual heterogeneity are needed to confirm and extend these findings.
1. Introduction
Eating disorder symptoms fluctuate across the menstrual cycle, and
within-person change in estradiol (E2) and progesterone (P4) account
for these phase differences (Baker, Girdler, & Bulik, 2012). Previous
work indicates that the mid-luteal phase of the menstrual cycle—when
both E2 and P4 are higher—is when binge eating and emotional eating
are highest (Edler, Lipson, & Keel, 2007; Klump et al., 2013). There is
also an interactive effect of changing levels of E2 and P4 on binge
eating and emotional eating such that binge eating and emotional
eating are exacerbated when both E2 and P4 are higher (Klump et al.,
2013, 2014). Importantly, work in this area has failed to attend to
important times of ovarian hormone change for women such as the
menopause transition (i.e., perimenopause). Indeed, perimenopause
has been hypothesized as a period of vulnerability for an eating dis-
order (Baker & Runfola, 2016) as initial reports suggest the prevalence
of eating disorders is increased in midlife women at perimenopause
(Mangweth-Matzek et al., 2013).
Perimenopause is characterized by changes in ovarian hormone
levels, namely erratic change in E2. At perimenopause, E2 dominance
can occur such that while P4 levels remain relatively low and stable
(when ovulation is not occurring), E2 levels can reach concentrations
higher than those observed during pre-menopause (Santoro, Brown,
Adel, & Skurnick, 1996). Further, differing trajectories of E2 change
have been observed during perimenopause with some women experi-
encing a slow E2 decline whereas others experience more frequent
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2.3. Measures
2.3.1. Estradiol and progesterone
Saliva samples were collected daily by the participants in their
home. Participants were instructed to collect 4 ml of saliva (indicated
by a line on the provided collection tubes) each morning within 30-
minutes of waking up and before brushing teeth, eating, drinking, or
smoking. Participants stored the collection tubes in a provided cooler in
their home freezer until returning for Visit 2.
2.3.2. Daily eating disorder symptoms
The Eating Pathology Symptom Inventory (EPSI; Forbush et al.,
2013) examined baseline and daily eating disorder symptoms. At
baseline, participants completed the full EPSI, which includes 8 sub-
scales, to assess various eating disorder symptoms, with higher scores
indicating more pathology. For the daily, evening assessment only the
Binge Eating and Body Dissatisfaction subscales were included. For the
daily assessment, the EPSI directions and question wording were
modified, with permission, to reflect symptoms experienced for that
day only (Forbush, personal communication). The EPSI was scored
according to the scoring instructions (Forbush et al., 2013).
2.3.3. Daily negative and positive affect
The Positive and Negative Affect Scale (PANAS; Watson et al., 1988)
was used to assess positive and negative affect.
2.4. Statistical analyses
2.4.1. Data coding and preparation
Analyses of within-person links between ovarian hormones and
eating disorder symptoms were modeled after those used by Klump
et al. (2013). In order to reduce impact of random environmental fac-
tors and hormone pulsatility, five-day rolling averages were calculated
for hormones, BE, BD, and negative affect. Next, each of these rolling
averages were converted to within-person Z scores based upon each
participant's mean and standard deviation for that repeated measures
variable across data collection. Use of these within-person standardized
values is ideal for examining the association between hormones and
eating disorder symptoms, because they index the extent to which
changes in a woman's hormones, relative to her own typical levels and
flux, predict changes away from her typical levels and flux in BE/BD
(Klump et al., 2008). Coding of menstrual cycle phase was considered;
however, given the erratic nature of observed hormone flux (which is
expected and indicative of the menopause transition) in the majority of
women, clear phases were not identifiable.
2.4.2. Multilevel modeling
Multilevel regression models tested study hypotheses. To account
for serial correlation of daily repeated measures, an autoregressive (t-1)
covariance structure was specified using a REPEATED statement in SAS
PROC MIXED. Denominator degrees of freedom were determined using
the Kenward-Roger method (Kenward & Roger, 1997). Hypotheses
were tested in two different models predicting daily BE or daily BD
from daily E2, daily P4, and their interaction with both daily negative
affect and Visit 1 body mass index (BMI) included as covariates.
3. Results
3.1. Descriptive information
Women reported a mean age of 45.9 (SD = 5.0), mean BMI of 33.1
(SD = 8.1), and a majority were Caucasian (n = 6), non-Hispanic
(n = 7). Most women had a college education (n = 5) and were mar-
ried or living with a partner (n = 7). At baseline, the mean BE score
was 18.2 (SD = 9.0) and the mean BD score was 20.3 (SD = 5.0),
which is slightly higher than young adult samples (Forbush et al.,
highs and lows (Tepper et al., 2012). Taken together with the com-
pelling evidence that changing E2 and P4 levels are involved in eating 
disorder symptom risk and fluctuation during young adulthood, this 
provides a strong rationale for exploring the role of ovarian hormones 
in eating disorder symptom fluctuation at perimenopause. Although the 
hormone changes that occur during young adulthood and at perime-
nopause are not identical, both represent periods of time when sig-
nificant change in ovarian hormones occurs—which may ultimately 
influence eating disorder risk (Baker & Runfola, 2016).
Thus, the aim of this pilot study was to preliminarily examine the 
interactive effect of changes in E2 and P4 on two core, transdiagnostic 
eating disorder symptoms: binge eating (BE: recurrent episodes of 
eating an unusually large amount of food in a short period time with an 
associated loss of control) and body dissatisfaction (BD: negative 
thoughts and feelings about one’s body) in midlife women during 
perimenopause.
1.1. Hypotheses
Based on previous studies including young adult women, (Klump 
et al., 2013, 2014) we hypothesize a significant interaction will be 
observed between E2 and P4 such that higher levels of BE and BD will 
be observed when both E2 and P4 are high. Because of the pilot nature 
of this study, we focus only on the interactive effect of changing E2 and 
P4, the finding that is most consistently observed in previous work in 
non-clinical samples, and do not interpret main effects.
2. Material and methods
2.1. Participants
Eligible participants included women aged 42–52 in early perime-
nopause who reported a history of at least two loss of control eating 
episodes in the month prior to study enrollment (n = 8). For study 
enrollment purposes only, loss of control eating was defined as an 
episode of eating in which the participant felt as if they could not resist 
the urge to eat and/or could not stop eating. Menopause status was 
determined based on menstrual bleeding patterns during the past year 
using STRAW criteria+10, (Harlow et al., 2007) the gold standard 
defining menopause status. Early perimenopause was defined as having 
a menstrual period in the previous 3-months but experiencing at least a 
7-day change in the length of the menstrual cycle between menstrua-
tion. Exclusion criteria included: surgical removal of ovaries and/or 
uterus; hormone supplementation or contraceptive use; steroid use in 
the previous 8-weeks; pregnancy or lactation in the past 6-months; or a 
genetic or medication condition known to influence ovarian hormone 
levels, weight, or appetite. This study was approved by the University of 
North Carolina IRB and participants provided written informed consent.
2.2. Procedure
Participants attended two study visits and completed in-home self-
assessments. At Visit 1 participant eligibility was confirmed, baseline 
measures were completed, height and weight were measured, and data 
collection procedures were reviewed. In-home self-assessments in-
cluded collecting saliva samples each morning for E2 and P4 assays and 
completing online study questionnaires at the end of each day. Self-
assessments were completed for one menstrual cycle (day one of menses 
to day one of menses) or 40-days, whichever occurred first. For com-
parability purposes, procedures for saliva collection and completion of 
the self-report questionnaires were modelled after previous studies 
(Edler et al., 2007; Klump, Keel, Culbert, & Edler, 2008, 2013). At Visit 
2 participants returned the saliva samples and were debriefed.
4. Discussion
Similar to young adults, within-person changes in ovarian hormones
interacted to predict changes in BE and BD symptom scores for women
at perimenopause. Our results are broadly consistent with the prior
finding in younger women (Klump et al., 2013, 2014; Racine et al.,
2012) that daily levels of P4 may shape the impact of daily E2 on eating
disorder symptoms yet how P4 shapes this impact may depend on the
symptom examined. Specifically, we observed that within the context of
low P4 (but not high P4), E2 was inversely associated with BD, but in
the context of high P4, E2 was positively associated with BD and BE.
Although simple slopes for BD were not significant, the follicular phase
of the menstrual cycle is the phase associated with high E2 and low P4.
The follicular phase follows menstruation, and menses may cyclically
impact body image (Jappe & Gardner, 2009). The cessation of men-
struation and associated increases in E2 may thus more robustly impact
BD. Taken together, cyclical ovarian hormone change may influence
eating disorder symptom vulnerability in midlife women.
The findings of this pilot study align with preclinical work demon-
strating a causal role of ovarian hormones on eating behavior. In
ovariectomized animals, administration of only E2 suppresses appetite
and eating behaviors via E2 receptors in the hypothalamus and the
nucleus of the solitary tract in the brainstem, whereas administration of
only P4 alone does not affect appetite (Butera, 2010). However, ad-
ministration of P4 in the context of E2 appears to facilitate an increase
in eating behaviors by reversing the appetite-suppressing effects of E2
(Kemnitz, Gibber, Lindsay, & Eisele, 1989). Indeed, the preliminary
findings in the present study are broadly consistent with these inter-
active effects of E2 and P4, since a protective effect of E2 on eating
disorder symptoms was present only at low P4 that was reversed under
conditions of high P4.
Because of the preliminary nature of this study, results must be
interpreted with caution and limitations considered. First is the pilot
sample size and thus associated concerns regarding power and gen-
eralizability. Because of the time intensive nature of the protocol, re-
plicating the sophisticated protocol that has been implemented in
young adults was favored at the expensive of sample size. Relatedly, as
a pilot, we limit our interpretation of the results to the simple slopes
given previous work in young adult samples has highlighted the im-
portance of this interactive effect. Therefore, our a priori aim was to test
Table 1
Multilevel Models Predicting Daily Eating Disorder Symptoms from 5-Day
Person-Standardized Rolling Averages of Ovarian Steroids.
Daily Outcome
Parameter Binge Eating Body Dissatisfaction
Estimate SE Estimate SE
Intercept −0.07 0.19 −0.04 0.19
BMI −0.02 0.19 −0.09 0.21
Daily Negative Affect 0.10 0.07 −0.06 0.06
E2 0.15 0.08 0.01 0.08
P4 −0.20* 0.10 −0.07 0.09
E2 x P4 0.16* 0.06 0.13** 0.05
Simple Slopes of E2 on Outcomes
Effect of E2 at Low P4 (-1 SD) −0.01 0.10 −0.12 0.09
Effect of E2 at High P4 (+1 SD) 0.31** 0.11 0.13 0.10
Note: *p < 0.05, **p < 0.01, ***p < 0.001. E2 = Estradiol,
P4 = Progesterone, BMI = Body Mass Index. Body mass index was sample-
standardized. E2, P4, Negative Affect, Binge Eating, and Body Dissatisfaction
represent 5-day rolling average levels that have been person-standardized (see
text for details). Significant fixed effects are shown in bold.
Fig. 1. Interactions of daily E2 and P4 in predicting daily binge eating (BE) and
body dissatisfaction (BD) z-scores. Note. *p < 0.05, **p < 0.01,
***p < 0.001. E2 = Estradiol, P4 = Progesterone. E2 and P4 represent 5-day
rolling average levels that have been person-standardized in order to reflect
within-person z-scores (see text for details). Significant fixed effects are shown
in bold.
2013). The mean score for negative affect at baseline was 15.0 
(SD = 5.4) and positive affect was 28.0 (SD = 6.0).
3.2. Intraclass correlations of repeated outcomes
Intraclass Correlations (ICCs) were calculated for unstandardized BE 
and BD. The ICC for BE was .59, indicating that 59% of the variance in 
BE was attributable to stable between-person differences; the ICC for 
BD was .84, indicating that 84% of the variance in BD was attributable 
to stable between-person differences. Although the preponderance of 
the variance in these outcomes was attributable to trait-like differences 
in symptoms, there was a significant degree of within-person variance. 
In order to replicate prior studies in this area (e.g., Edler et al., 2007; 
Klump et al., 2013), we utilize person-standardized outcomes, which 
means that the daily outcomes contain only within-person variance, and 
therefore no between-person predictors were included (since between-
person variance in outcomes had been removed).
3.3. Effects of ovarian hormones on daily eating disorder symptoms
Consistent with prior work, interactions of daily E2 and P4 were 
observed for both BE and BD (Table 1). Simple slopes of E2 on BE in-
dicated that increasing E2 was strongly associated with higher BE when 
P4 was high (Fig. 1, top panel; p = 0.005), but was not associated with 
BE when P4 was low (Fig. 1, top panel; p = 0.91). Simple slopes of E2 
on BD indicated that increasing E2 was also associated with higher BD 
when P4 was high (see Fig. 1, bottom panel; p = 0.17), but increasing 
E2 was associated with lower BD when P4 was low (see Fig. 1, bottom 
panel; p =  0.17). However, simple slopes for BD were not significant. 
Post-hoc power analyses indicated power was only adequate to detect 
large effect sizes; however, the number of observations in this pilot 
study was similar to those utilized in other samples (Edler et al., 2007; 
Klump et al., 2008). Results remained the same whether or not current 
BMI and daily negative effect were entered as between and within-
person covariates, respectively.
5. Conclusions
This is the first study to examine the influence of fluctuations in
ovarian hormones on changes in eating disorder symptoms during a
significant time of reproductive hormone flux for women. Similar to
young adults, within-person change in ovarian hormones predicted
changes in symptoms of BE and BD for women at perimenopause.
Together, this suggests ovarian hormones may play a role in eating
disorder etiology across the lifespan. Continuing to address the impact
of ovarian hormones on eating disorder symptoms may lead to novel
and personalized treatment approaches. For example, ovarian hormone
stabilization or supplementation may be beneficial for some women
with or at risk for an eating disorder—in particular during periods of
significant reproductive hormone flux. Given perimenopause is defined
by chaotic change in ovarian hormones, in particular E2, it may be a
significant time of risk for eating disorder symptom onset, relapse, or
exacerbation (Baker, et al., 2012).
Finally, experimental studies are needed to make causal inter-
ferences about the role of ovarian hormones in the risk for eating dis-
order symptoms and future studies need to include key moderators
(e.g., negative life events) of response to ovarian hormone change.
Perimenopause represents a quasi-experimental design to address the
impact of changing ovarian hormones on behavior in humans.
Continuing to address eating disorder symptoms during midlife and
beyond is vital given women experience significant changes in ovarian
hormones during this period of development.
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the interactive effect of E2 and P4 on eating disorder symptoms in a 
midlife sample and compare findings to young adults. Second, given the 
erratic changes in E2 and P4 that characterize the perimenopause (as 
reflected in the samples collected here), we were unable to determine 
cycle phase. Third, we used a self-report questionnaire assessment of 
binge eating, which may not directly reflect DSM-defined binge eating. 
Finally, our sample only included women in early perimenopause. 
There may be a differential effect of ovarian hormones on eating dis-
order symptoms across the stages of menopause and post-menopause.
